Half-year report · HY
8086.TEDINET S100X3LO
Period2025-04-01 → 2025-09-30
Filed2025-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥317.4bn | 2025-04-01 → 2025-09-30 | Cons. | Net sales |
| Revenue | ¥644.6bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥312.0bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Operating income | ¥15.3bn | 2025-04-01 → 2025-09-30 | Cons. | Operating income |
| Operating income | ¥13.5bn | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | ¥8.2bn | 2025-04-01 → 2025-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥10.8bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥4.5bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥12.4bn | 2025-04-01 → 2025-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥4.1bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥5.9bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥5.1bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥129m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥6.6bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss |
| Net income | ¥813m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥1.15T | at 2025-09-30 | Cons. | Assets |
| Total assets | ¥1.17T | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥1.17T | at 2024-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥855.9bn | at 2025-09-30 | Cons. | Liabilities |
| Total liabilities | ¥858.9bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥297.7bn | at 2025-09-30 | Cons. | Net assets |
| Net assets / equity | ¥311.6bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥298.1bn | at 2024-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥110.0bn | at 2025-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥106.7bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥104.9bn | at 2025-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥101.7bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥85.0bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥96.6bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥16.9bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥68.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥15.0bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥13.7bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥71.9bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥54.8bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥1.6bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥5.4bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥23.3bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥36.21 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥31.36 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥0.79 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥32.08 | 2025-04-01 → 2025-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥27.78 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥0.7 | 2024-04-01 → 2024-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 20.7% | at 2025-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 21.6% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 22.1% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 54
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2025-04-01 → 2025-09-30 | ¥3.5bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2025-04-01 → 2025-09-30 | ¥499m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥3.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2025-04-01 → 2025-09-30 | ¥431m |
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2025-09-30 | −¥40.3bn |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2025-09-30 | −¥40.3bn |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2025-09-30 | −¥13.1bn |
| Medical Treatment Relatedreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥256.3bn |
| Medical Treatment Relatedreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥252.6bn |
| Medical Treatment Relatedreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥3.8bn |
| Medical Treatment Relatedreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥23.9bn |
| Medicine Relatedreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥66.7bn |
| Medicine Relatedreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥37.1bn |
| Medicine Relatedreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥29.6bn |
| Medicine Relatedreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥4.9bn |
| Pharma Packagingreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥31.2bn |
| Pharma Packagingreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥27.2bn |
| Pharma Packagingreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥4.0bn |
| Pharma Packagingreportable segment | segment profit | 2025-04-01 → 2025-09-30 | −¥861m |
| —segment total | revenue | 2025-04-01 → 2025-09-30 | ¥354.2bn |
| —segment total | revenue external | 2025-04-01 → 2025-09-30 | ¥316.9bn |
| —segment total | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥37.3bn |
| —segment total | segment profit | 2025-04-01 → 2025-09-30 | ¥28.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-04-01 → 2025-09-30 | ¥357.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-04-01 → 2025-09-30 | ¥317.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥40.3bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-04-01 → 2025-09-30 | ¥28.4bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-04-01 → 2024-09-30 | ¥3.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-04-01 → 2024-09-30 | ¥383m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥2.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-04-01 → 2024-09-30 | −¥272m |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥39.9bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥39.9bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥14.9bn |
| Medical Treatment Relatedreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥245.6bn |
| Medical Treatment Relatedreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥242.1bn |
| Medical Treatment Relatedreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥3.6bn |
| Medical Treatment Relatedreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥24.5bn |
| Medicine Relatedreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥68.4bn |
| Medicine Relatedreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥38.0bn |
| Medicine Relatedreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥30.4bn |
| Medicine Relatedreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥3.2bn |
| Pharma Packagingreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥34.9bn |
| Pharma Packagingreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥31.6bn |
| Pharma Packagingreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥3.3bn |
| Pharma Packagingreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥931m |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥348.9bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥311.6bn |
| —segment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥37.3bn |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥28.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥351.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥312.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥39.9bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥28.4bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 645
| Item | Context | Value | Unit |
|---|---|---|---|
| Filer name in english | FilingDateInstant | NIPRO CORPORATION | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | Japan GAAP | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | cte | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | － | |
| Current fiscal year start date | FilingDateInstant | 2025-04-01 | |
| Current period end date | FilingDateInstant | 2025-09-30 | |
| Type of current period | FilingDateInstant | HY | |
| Current fiscal year end date | FilingDateInstant | 2026-03-31 | |
| Previous fiscal year start date | FilingDateInstant | 2024-04-01 | |
| Comparative period end date | FilingDateInstant | 2024-09-30 | |
| Previous fiscal year end date | FilingDateInstant | 2025-03-31 | |
| Next fiscal year start date | FilingDateInstant | － | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | － | |
| Amendment flag | FilingDateInstant | false | |
| Identification of document subject to amendment | FilingDateInstant | － | |
| Report amendment flag | FilingDateInstant | false | |
| Xbrl amendment flag | FilingDateInstant | false | |
| Business results of group (text) | FilingDateInstant | Text · Plus | |
| Description of business (text) | FilingDateInstant | Text · Plus | |
| Business risks (text) | FilingDateInstant | Text · Plus | |
| Management analysis of financial position operating results and cash flows (text) | FilingDateInstant | Text · Plus | |
| Critical contracts (text) | FilingDateInstant | Text · Plus | |
| Total number of shares (text) | FilingDateInstant | Text · Plus | |
| Issued shares total number of shares etc (text) | FilingDateInstant | Text · Plus | |
| Class issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)普通株式 | |
| Name of financial instruments exchange on which securities are listed or authorized financial instruments business association to which securities are registered | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)東京証券取引所プライム市場 | |
| Description issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)単元株式数は100株であります。 | |
| Details of employee share option program (text) | FilingDateInstant | Text · Plus | |
| Other information on share acquisition rights (text) | FilingDateInstant | Text · Plus | |
| Exercises etc of moving strike convertible bonds etc (text) | FilingDateInstant | Text · Plus | |
| Changes in number of issued shares stated capital etc (text) | FilingDateInstant | Text · Plus | |
| Major shareholders (text) | FilingDateInstant | Text · Plus | |
| Name major shareholders | InterimInstant_No1MajorShareholdersMember | Original text (Japanese)日本マスタートラスト信託銀行株式会社（信託口） | |
| Address major shareholders | InterimInstant_No1MajorShareholdersMember | Original text (Japanese)東京都港区赤坂１丁目８番１号 赤坂インターシティＡＩＲ | |
| Name major shareholders | InterimInstant_No2MajorShareholdersMember | Original text (Japanese)日本電気硝子株式会社 | |
| Address major shareholders | InterimInstant_No2MajorShareholdersMember | Original text (Japanese)滋賀県大津市晴嵐２丁目７番１号 | |
| Name major shareholders | InterimInstant_No3MajorShareholdersMember | Original text (Japanese)株式会社日本カストディ銀行（信託口） | |
| Address major shareholders | InterimInstant_No3MajorShareholdersMember | Original text (Japanese)東京都中央区晴海１丁目８－12 | |
| Name major shareholders | InterimInstant_No4MajorShareholdersMember | Text · Plus | |
| Address major shareholders | InterimInstant_No4MajorShareholdersMember | Text · Plus | |
| Name major shareholders | InterimInstant_No5MajorShareholdersMember | Original text (Japanese)ＪＰモルガン証券株式会社 | |
| Address major shareholders | InterimInstant_No5MajorShareholdersMember | Original text (Japanese)東京都千代田区丸の内２丁目７－３ 東京ビルディング | |
| Name major shareholders | InterimInstant_No6MajorShareholdersMember | Text · Plus | |
| Address major shareholders | InterimInstant_No6MajorShareholdersMember | Text · Plus | |
| Name major shareholders | InterimInstant_No7MajorShareholdersMember | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |